HLA Class I Ligandome Modulation by Zapnometinib and Influenza A Virus in Lung Cells

A 2026 study by Hazem Hamza provides immunopeptidomic data from human lung adenocarcinoma Calu-3 cells. The dataset, shared under CC-BY-4.0, contains results from label-free LC–MS/MS analysis of HLA-I–presented peptides following Influenza A virus H3N2/Fukui infection and treatment with the MEK inhibitor zapnometinib. It includes measurements of peptide abundance changes and functional pathway enrichment analyses.

Use Cases

• Analyzing allotype-specific changes in HLA-I-presented peptide abundance based on immunopeptidomic results.
• Investigating pathway-specific modulation of antiviral responses based on functional annotation analysis.
• Studying the effects of MEK inhibition on ligandome plasticity without bulk HLA-I expression changes as described.
• Comparing the immunomodulatory impact of viral infection versus drug treatment on peptide presentation.

Strengths

• Dataset is based on label-free LC–MS/MS analysis, a standard method for immunopeptidomics.
• Includes quantified results such as fold changes (1.01-1.13) and statistical significance (adjusted p < 0.05) for ligand subsets.
• Specific pathway enrichments are identified, such as interferon-induced and cell cycle pathways.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small (18.8 KB), indicating a limited scope of presented results.

Provenance

Source

figshare, author Hazem Hamza

Collection Method

Label-free LC–MS/MS analysis of HLA-I–presented peptides from Calu-3 cells infected with Influenza A virus and/or treated with zapnometinib.

Freshness

Last updated 2026-05-26 06:02:13; freshness should be verified.